Filter by Category: Clinical Trial Support

Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for the treatment of nosocomial pneumonia.

Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for the treatment of nosocomial pneumonia. by Mendes RE, Deshpande LM, Smyth DS, Shopsin B, Farrell DJ and Jones RN published in J. Clin. Microbiol. 2012; 50 (11): 3694-3702

Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial.

Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial. by Farrell DJ, Turner LL, Castanheira M and Jones RN published in Diagn. Microbiol. Infect. Dis. 2012; 74 (1): 73-74

Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from Phase IV clinical trial for linezolid.

Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from Phase IV clinical trial for linezolid. by Mendes RE, Sader HS, Deshpande LM, Diep BA, Chamers HF, Jones RN published in J. Clin. Microbiol. 2010; 48 (2): 568-574

Molecular characterization of Staphylococcus aureus isolates from a 2005 clinical trial of uncomplicated skin and skin structure infections.

Molecular characterization of Staphylococcus aureus isolates from a 2005 clinical trial of uncomplicated skin and skin structure infections. by Jones RN, Nilius AM, Akinlade BK, Deshpande LM and Notario GF published in Antimicrob. Agents Chemother. 2007; 51 (9): 3381-3384

Safety and efficacy of gatifloxacin in community-acquired pneumonia: Rationale for the Tequin Clinical Experience Study (TeqCES).

Safety and efficacy of gatifloxacin in community-acquired pneumonia: Rationale for the Tequin Clinical Experience Study (TeqCES). by Mandell LA published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 65-67

Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5,889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains.

Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5,889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. by Jones RN, Pfaller MA, Fuchs PC, Aldridge K, Allen SD, and Gerlach EH published in Diagn. Microbiol. Infect. Dis. 1989; 12 (6): 489-494